Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
NeoGenomics, Inc.
NEO
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $389.9M
$15.16
▲ +1.27%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$4.72 - $15.56
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 102.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Specialized cancer-focused testing expertise with multi-modal diagnostic capabilities
- Geographically diversified laboratory network across US, Europe, and Asia reducing operational risk
- Strategic alliance with Inivata Limited providing advanced molecular testing capabilities
- Established relationships with major pharmaceutical companies creating recurring revenue streams
- Comprehensive test menu reducing client need for multiple laboratory vendors
Bear Case
2 risks
- Above-average volatility (beta 1.8).
- High premium - requires strong execution
Growth
Turning profitable
Rising global cancer incidence driving demand for diagnostic testing services
Value
High premium - requires strong execution
Momentum
Hot
+87.1% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying NEO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 27, 2026
APR 28, 2026
Reported EPS of $0.01 vs $0.01 consensus (+73.0% surprise). Revenue of $186.7M vs $184.5M expected (+1.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+73.0%
Next: Apr 27, 2026
Revenue trend · last 8Q
—
—
+11%
+8%
+10%
+12%
+11%
+11%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$164.5M
$167.8M
$172.0M
$168.0M
$181.3M
$187.8M
$190.2M
$186.7M
Margins · last 8Q
Gross
—
Operating
—
Profit
-9.2%
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$25.00
▲ +64.9% vs $15.16
Latest: Leerink · $25.00 · Apr 29, 2026
1 analyst covering
vs Industry
How NEO stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related